Biotechnology company BiVictriX Therapeutics plc (AIM: BVX) announced on Wednesday that it has received FDA Orphan Drug Designation (ODD) for BVX001 in Acute Myeloid Leukaemia (AML) treatment.
FDA INTERACT meeting completion aligns with development plans for BVX001, a novel twin antigen targeting bispecific Antibody Drug Conjugate (bxADC), offering potential financial incentives and market exclusivity.
ODD provides tax credits and potential seven-year marketing exclusivity upon FDA approval for therapies targeting diseases affecting less than 200,000 people in the US.
BiVictriX focuses on developing highly selective cancer therapeutics, leveraging a proprietary pipeline of Bi-Cygni Antibody Drug Conjugates designed to target cancer-specific antigen pairs.
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Psilera collaborates with Hesperos for PSIL-006 preclinical modelling for frontotemporal dementia
Myosin Therapeutics' MT-125 cleared by US FDA to initiate first-in-human trial in glioblastoma
Ondine's Steriwave proven effective against deadly Mucor fungus
AB Science receives EMA approval to extend Masivet shelf life to four years
Hemispherian's GLIX1 receives positive EU opinion for orphan designation in glioma
Arvinas and Pfizer submit FDA application for vepdegestrant in ESR1-mutated breast cancer
NRx Pharmaceuticals files ANDA for preservative-free IV ketamine
Innovent's IBI363 granted second breakthrough therapy designation in China
Implantica reports positive NICE guidance for RefluxStop procedure in UK hospitals